Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

KIVEXA Israel - English - Ministry of Health

kivexa

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - film coated tablets - abacavir as sulfate 600 mg; lamivudine 300 mg - nucleoside and nucleotide reverse transcriptase inhibitors - kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.

KIVEXA Israel - English - Ministry of Health

kivexa

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - film coated tablets - abacavir as sulfate 600 mg; lamivudine 300 mg - kivexa is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.28/10/2018 עדכון התוויה: kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and, adolescents s of and children weighing at least 25 kg.שינוי משטר מינון:adults, adolescents and children weighing at least 25 kg:the recommended dose of kivexa is one tablet once daily.children under 25 kg: kivexa should not be administered children who weigh less than 25 kg because it is a fixed dose tablet that cannot be dose reduced.paediatric population: the safety and efficacy of kivexa in children weighing less than 25 kg has not been established. currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on posology can be made.

Altargo Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

altargo

glaxo operations uk ltd. (trading as glaxo wellcome operations) - retapamulin - ointment - 10mg/g

Votrient 400mg tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

votrient 400mg tablets film-coated

glaxo wellcome s.a. - pazopanib - tablets film-coated - 400mg

Votrient 200mg tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

votrient 200mg tablets film-coated

glaxo wellcome s.a. - pazopanib - tablets film-coated - 200mg

Zeffix 100mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zeffix 100mg tablets

glaxosmithkline uk ltd - lamivudine - tablet - 100mg

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) European Union - English - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Agenerase European Union - English - EMA (European Medicines Agency)

agenerase

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

Revolade Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

revolade

glaxo wellcome s.a. - eltrombopag (eltrombopag olamine) - tablets film-coated - 25mg